COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities. Current guidelines recommend initial combination therapy, but evidence is lacking for patients with significant comorbidities who are often excluded from clinical trials. The COMMODITIES trial is a multicenter, randomized, controlled study designed to compare the efficacy and safety of initial dual oral combination therapy (tadalafil and ambrisentan) versus oral monotherapy in newly diagnosed PAH patients with at least two cardiovascular comorbidities. The study aims to provide robust evidence to guide treatment strategies in this high-risk population.

NCT Number	NCT07245680
Lead Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions	Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
Enrollment	186 participants
Start Date	2026-04-28
Primary Completion	2029-02-14 (estimated)
Study Completion	2029-02-14 (estimated)
Updated on ClinicalTrials.gov	2026-05-13